Results 81 to 90 of about 52,744 (222)

IMMUNOPATHOGENESIS OF MYASTHENIA GRAVIS (REVIEW) [PDF]

, 2018
Myasthenia gravis is a progressive autoimmune disease, which characterized by the production of antibodies to the structures of the neuromuscular junction.
E. D. Gasymly
core   +1 more source

Dental Care in Patients with Myasthenia Gravis

Česká Stomatologie a Praktické Zubní Lékařství, 2010
Myasthenia gravis is an autoimmune disease in the neuromuscular transmission, causing muscular weakness and fatique especially in the facial and pharyngeal muscles.
J. Piťha
doaj  

Myasthenia gravis associated KEGG pathways.

, 2014
Myasthenia gravis associated KEGG pathways.
Huixue Zhang (614029), Weizhi Wang (124642), Jianjian Wang (288375), Lihua Wang (14548), Yuze Cao (614028), Lixia Chen (614030), Ronghong Li (104426), Qinghua Tian (614031), Lili Yang (116313), Xuesong Sun (424554), Shangwei Ning (104422), Xia Li (14984)   +11 more
core   +1 more source

Evidence of underdiagnosis of myasthenia gravis in older people. [PDF]

, 2003
BACKGROUND: Myasthenia gravis is a potentially serious but treatable muscle disease caused by autoantibodies directed at the acetylcholine receptor (AChR) on the postsynaptic membrane of the neuromuscular junction.
Robertson, Neil, Rothwell, P., Grimley Evans, J., Vincent, A, Buckley, C., UK Myasthenia Gravis Survey, Clover, L.   +6 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Coexistence of Pernicious Anemia and Myasthenia Gravis—A Rare Combination of Autoimmune Diseases in Taiwan

Journal of the Formosan Medical Association, 2006
About 5-10% of patients with myasthenia gravis concomitantly have other autoimmune diseases. However, the coexistence of myasthenia gravis and pernicious anemia is rare.
Kuo-Hsuan Chang, Rong-Kuo Lyu, Long-Sun Ro, Yih-Ru Wu, Chiung-Mei Chen   +4 more
doaj   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

RARITY OF MYASTHENIA GRAVIS IN NORTHERN NIGERIANS [PDF]

, 2002
This is a 10 year retrospective review of patients managed at the Ahmadu Bello Teaching hospital, Zaria, Nigeria for myasthenia gravis. Only 4 patients were identified from the hospital's records.
A.G. Bakari, G.C. Onyernelukwe
core   +3 more sources

Myasthenia Gravis: Recent Developments

, 2005
To: 1. Describe the potential mechanisms for preferential involvement of ocular muscles by myasthenia gravis; 2. Discuss risks and benefits of corticosteroid use for treatment of ocular myasthenia; 3. Appropriately use edrophonium, serum autoantibody and
Henry J. Kaminski, MD
core  

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source